MedTrace Logo

Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee

NCT05059626 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2024-11-05

No results posted yet for this study

Summary

Purpose: To determine the effects of SERM and simvastatin interventions on endothelial dysfunction in women with endometriosis.

Hypothesis: Treatment with the SERM (bazedoxifene + conjugated estrogen) or with simvastatin will decrease systemic inflammation and improve specific measures of cardiovascular function including endothelium-dependent vasodilation.

Conditions

  • Endometriosis

Interventions

DRUG

simvastatin 10mg

Simvastation acts as a systemic LOX inhibitor.

DRUG

Bazedoxifene 20/Estrogens,Con 0.45Mg Tb

Duavee is a selective estrogen receptor modulator.

Sponsors & Collaborators

  • The John B. Pierce Laboratory

    collaborator OTHER

  • Penn State University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2025-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05059626 on ClinicalTrials.gov